Recruiting PHASE1 INTERVENTIONAL 1-arm
NCT06970795
A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors
An Open-lable, Multicenter Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of SYS6040 for Injection as a Single Agent in Participants With Advanced Solid Tumors
Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
Interventions
SYS6040 for injection
Updated 1 time since 2025 Last updated: May 6, 2025 Started: Apr 10, 2025 Primary completion: Feb 28, 2027 Completion: Nov 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE1 clinical study on Other Advanced Solid Tumors and Small Cell Lung Cancer, this trial is actively recruiting participants. The trial is conducted by CSPC Megalith Biopharmaceutical Co.,Ltd. and has accumulated 1 data snapshot since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Data source: CSPC Megalith Biopharmaceutical Co.,Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .